Source link : https://www.newshealth.biz/health-news/modified-donanemab-dosing-may-reduce-aria-e-risk-in-early-alzheimers/
Modified titration of donanemab (Kisunla) for early Alzheimer’s disease significantly reduced the frequency of amyloid-related imaging abnormalities with edema and effusion (ARIA-E) compared to standard dosing, while maintaining sufficient amyloid reduction, according to findings from the TRAILBLAZER-ALZ 6 trial presented at the Clinical Trials on Alzheimer’s Disease conference in Madrid. In this exclusive MedPage Today […]
Author : News Health
Publish date : 2024-12-03 19:12:08
Copyright for syndicated content belongs to the linked Source.